CN1126539C - Application of tanshinone in preparing medicine for treating tumor - Google Patents
Application of tanshinone in preparing medicine for treating tumor Download PDFInfo
- Publication number
- CN1126539C CN1126539C CN 99121460 CN99121460A CN1126539C CN 1126539 C CN1126539 C CN 1126539C CN 99121460 CN99121460 CN 99121460 CN 99121460 A CN99121460 A CN 99121460A CN 1126539 C CN1126539 C CN 1126539C
- Authority
- CN
- China
- Prior art keywords
- cell
- tanshinone
- tumor
- tanshinones
- differentiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930183118 Tanshinone Natural products 0.000 title claims abstract description 85
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 208000032839 leukemia Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 29
- 230000001939 inductive effect Effects 0.000 abstract description 24
- 230000006907 apoptotic process Effects 0.000 abstract description 21
- 241001465754 Metazoa Species 0.000 abstract description 16
- 230000024245 cell differentiation Effects 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 12
- 238000012360 testing method Methods 0.000 abstract description 6
- 230000002147 killing effect Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 43
- 230000004069 differentiation Effects 0.000 description 20
- 238000011282 treatment Methods 0.000 description 19
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 16
- 229930002330 retinoic acid Natural products 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 108010017842 Telomerase Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- -1 hydroxyl tanshinone Chemical compound 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 4
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 4
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 108700041737 bcl-2 Genes Proteins 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 108700025694 p53 Genes Proteins 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 201000010174 renal carcinoma Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- QHGPIJMPUOVBOL-UHFFFAOYSA-N 4,4,8-trimethyl-2,3-dihydro-1h-naphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound O=C1C2=CC=C(C(CCC3)(C)C)C3=C2C(=O)C2=C1C(C)=CO2 QHGPIJMPUOVBOL-UHFFFAOYSA-N 0.000 description 2
- XYKZSUXWBGUGQV-UHFFFAOYSA-N 4,8-dimethylnaphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound CC1=CC=CC2=C(C(C=3OC=C(C=3C3=O)C)=O)C3=CC=C21 XYKZSUXWBGUGQV-UHFFFAOYSA-N 0.000 description 2
- XDUXBBDRILEIEZ-UHFFFAOYSA-N 6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-UHFFFAOYSA-N 0.000 description 2
- 101150080924 CNE1 gene Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 108700025906 fos Genes Proteins 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000054896 human PML Human genes 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 108700024542 myc Genes Proteins 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000004765 promyelocyte Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
- 101150111660 53 gene Proteins 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000007528 DNA Polymerase III Human genes 0.000 description 1
- 108010071146 DNA Polymerase III Proteins 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- PRYXPGFZVGZNBL-ADLFWFRXSA-N salviol Chemical compound CC(C)c1cc2CC[C@H]3C(C)(C)C[C@H](O)C[C@]3(C)c2cc1O PRYXPGFZVGZNBL-ADLFWFRXSA-N 0.000 description 1
- AJSGWTLZEUBGFV-UHFFFAOYSA-N salviol Natural products CC(C)c1cc2CCC3C(CC(O)CC3(C)C)c2cc1O AJSGWTLZEUBGFV-UHFFFAOYSA-N 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a new application of tanshinone in the preparation of a medicine for treating tumor. The tanshinone has the advantages of extensive material source, cheap price and simple preparation process. Animal in-vivo experiments and clinical tests prove that tanshinone has favorable effects on killing tumor cells, inducing tumor cell differentiation and inducing tumor cell apoptosis and has little side effects. Tanshinone has a favorable application prospect, and the present invention develops a new application for tanshinone.
Description
The present invention relates to the purposes of salviamiltiorrhizabung extract TANSHINONES in the preparation pharmaceutical product, the particularly application of TANSHINONES in the medicine of preparation treatment tumor.
The invention still further relates to the pharmaceutical composition of treatment tumor, wherein contain TANSHINONES.
Radix Salviae Miltiorrhizae is the root of Labiatae salvia (Salvia miltiorrhiza Bunge), is blood-activating and stasis-removing commonly used
[1]Its cold nature, bitter in the mouth, nontoxic.The function that has promoting blood circulation to restore menstrual flow, removing heat from blood detumescence, relieving restlessness to clear away heart-fire.Compendium of Material Medica
[2]On records such as " superfluous toxic swelling erysipelas of Treated with Radix Salviae Miltiorrhizae malignant boil scabies, wart and evacuation of pus pain relieving, growth muscle " is arranged.(Tanshinone Tan) is the ether or the ethanol extraction of Radix Salviae Miltiorrhizae root to TANSHINONES.For seeking the effective ingredient in the Radix Salviae Miltiorrhizae, study the relation between its pharmacological action and chemical constitution, lot of domestic and foreign scholar has carried out extensive work, successively separate 15 kinds of compositions that obtain Radix Salviae Miltiorrhizae, measured their structural formula (see figure 1) simultaneously, and with these compositions called after Tanshinone I successively (I), tanshinone (II), Tanshinone II B (III), cryptotanshinone (IV), iso tanshinone I (V), iso tanshinone IIA (VI), different cryptotanshinone (VII), hydroxyl tanshinone (VIII), Methyl tanshinoate (IX), Miltirone (X), Salviol (XI), dihydrotanshinone I (XII), neotanshinone A (XIII), neotanshinone B (XIV) and neotanshinone C (XV)
[3]Studies show that by these 15 kinds of constituent structure tanshinone all contains o-quinone or para-quinoid structure as the effective ingredient of Radix Salviae Miltiorrhizae to Radix Salviae Miltiorrhizae.Because the quinones composition is reduced easily and changes the diphenols derivant into, the oxidized again quinone that changes into easily again of the latter plays the electronics transfer function in transition process.Simultaneously, their metabolites in vivo participate in the multiple biochemical reaction of body, and as the coenzyme of biological respinse some biochemical reaction are risen and to promote or interference effect, thereby show multiple pharmacological effect, as antibiotic, antiviral etc.
Discover, TANSHINONES has the natural anti-oxidation effect, Chinese Academy of Medical Sciences's tanshinone that biophysics has been studied is to hepatocyte lipid peroxidation product and the interactional influence of DNA, and reach a conclusion, think that tanshinone is a kind of new effective lipid within endothelial cells peroxidating product and interactional inhibitor of DNA.It may be to block the chain reaction of lipid peroxidation by eliminating the lipid free radical to the protective effect of DNA, suppresses the generation of DNA addition product, thereby has reduced the latter's cytotoxicity
[4]
TANSHINONES mainly has the cardiovascular pharmacological effect clinically, but its atherosclerosis
[5], have the myocardial infarction area of dwindling, reduce myocardial oxygen consumption, thrombosis and platelet aggregation all had inhibitory action
[6,7]Simultaneously, Tanshinone II B (III), cryptotanshinone (IV), Methyl tanshinoate (IX), hydroxyl tanshinone (VIII), dihydrotanshinone I (XII) have stronger inhibitory action to staphylococcus aureus and Resistant strain thereof.Tanshinone I (I), tanshinone (II), cryptotanshinone (IV), hydroxyl tanshinone (VIII) are to Bacillus tuberculosis (H
37RV) bacterial strain has stronger inhibitory action
[3]
TANSHINONES is mainly used in treatment coronary heart disease, acne, dysmenorrhea, insomnia and anti-inflammation clinically, and the golden Portugal bacterium in amygdala inflammation, furuncle of ear, suppurative osteomyelitis, the burn infects, and effect is remarkable
[8]
At present, malignant tumor constitutes threat greatly to human health, and the treatment of malignant tumor mainly contains approach such as operation, chemotherapy, radiotherapy.For most of solid tumors, common treatment means is for performing the operation in conjunction with radiotherapy (radiotherapy) and chemotherapy (chemotherapy), chemotherapeutics is by the cytotoxic effect kill tumor cell to tumor cell, the defective that but most of chemotherapeutics are toxic greatly, side effect is big, many patients are because of being difficult to bear the toxicity therapy discontinued of chemotherapeutics; And on the other hand, some tumor cell is because of undesirable to chemotherapeutics or the insensitive therapeutic effect that makes of radiotherapy ray.Therefore, need to seek, develop the antitumor drug that new toxic and side effects is little, therapeutic effect is good clinically.
The induction-differential therapy malignant tumor is the new way of cancerous protuberance treatment, the fundamental difference of induction-differential therapy and traditional chemical treatment is not killing tumor cell, but transform to normal cell by drug-induced tumor cell, simultaneously normal cell there is not lethal effect, and side effect such as rare bone marrow depression.So induction-differential therapy is compared with other treatment approach bigger superiority is arranged, and causes the extensive attention of medical circle thus
[9]1986, the success of all-trans-retinoic acid (ATRA) induction-differential therapy acute promyelocytic leukemic (APL) promoted the basis of induction-differential therapy malignant tumor and the progress of clinical research greatly
[10]But retinoic acid related syndromes and the drug resistance that takes place have fast limited the clinical practice of this medicine, therefore, press for the new differentiation agent of inducing efficient, low toxicity of searching and improve the induction-differential therapy of tumor
[11-13]
At the defective of prior art, the object of the present invention is to provide the new purposes of TANSHINONES in preparation medicine for treating tumor thing; Described treatment tumor includes but not limited to killing tumor cell, inducing tumor cell differentiation and inducing apoptosis of tumour cell.
According to an aspect of the present invention, the present invention relates to the application of TANSHINONES as preparation medicine for treating tumor thing, described tumor includes but not limited to leukemia, hepatocarcinoma, pulmonary carcinoma, cerebral glioma, osteosarcoma, cervical cancer, ovarian cancer, colorectal cancer, gastric cancer, cancer of pancreas, renal carcinoma, bladder cancer, laryngeal carcinoma, nasopharyngeal carcinoma.
According to a further aspect in the invention, the present invention relates to the application of TANSHINONES as the medicine of induction-differential therapy tumor, described tumor includes but not limited to leukemia, pulmonary carcinoma, hepatocarcinoma, cerebral glioma, osteosarcoma, gastric cancer, colorectal cancer, renal carcinoma, bladder cancer.
According to another aspect of the invention, the present invention relates to the application of TANSHINONES as the medicine of apoptosis-induced treatment tumor, described tumor includes but not limited to leukemia, pulmonary carcinoma, hepatocarcinoma, cerebral glioma, osteosarcoma, straight colon cancer, gastric cancer, renal carcinoma, bladder cancer.
In order to understand essence of the present invention better, below by to TANSHINONES lethal effect, the introduction of inducing differentiation and apoptosis-induced experimental study of effect result, describe the present invention in detail:
One. the effect of TANSHINONES killing tumor cells
Experiment in vitro shows that TANSHINONES has lethal effect to kinds of tumor cells, and the tanshinone of 1 μ g/ml is to human promyelocytic leukemia cell strain HL-60, the NB of In vitro culture
4, the slow grain of people erythroleukemia cell strain K562, human hepatoma cell strain SMMC-7721, human lung carcinoma cell line SPC-A-1, human stomach cancer cell line SGC7901, human nasopharyngeal carcinoma cell line CNE1 etc. all have lethal effect.
Two. differentiation of TANSHINONES inducing tumor cell and effect of apoptosis
Find that after deliberation the TANSHINONES of non-toxic can be induced kinds of tumor cells differentiation and apoptosis.The tanshinone of employing 0.25~0.5 μ g/ml acts on the human promyelocytic leukemia cell strain (HL-60 and the NB that are in exponential phase of In vitro culture respectively
4), the slow grain of people erythroleukemia cell strain (K562), human hepatoma cell strain (SMMC-7721), go into lung cancer cell line (SPC-A-1), human stomach cancer cell line (SGC7901) and human nasopharyngeal carcinoma cell line CNE1, with 0.01%DMSO (solvent of Tan IIA) is blank, with the clinical positive contrast of differentiation medicament all-trans-retinoic acid (ATRA) of inducing commonly used at present, behind the drug effect 5 days, collecting cell, carry out light microscopic, electron microscopic observation cellular morphology, calculate tumor cell induction differentiation rate, apoptosis rate and growth inhibition ratio; Flow cytometer (Flow cytometry) carries out cell cycle analysis and gene expression detects, and the results are shown in Table 1
The external evoked differentiation of table 1 TANSHINONES
*Compare with blank group (DMSO), there were significant differences in P<0.01
*Compare P>0.05, no significant difference with positive controls (ATRA)
The result shows, but the TANSHINONES inducing tumor cell to optimum or normal cell differentiation, its induction of differentiation does not have significant difference with the differentiation agent ATRA that induces that uses at present clinically.In addition, TANSHINONES also has the effect (heavy dose of TANSHINONES has the cell toxicant lethal effect) of inducing apoptosis of tumour cell in the inducing tumor cell differentiation, illustrates that the non-toxic TANSHINONES has the effect of treatment tumor equally.
Three. the mechanism of TANSHINONES treatment tumor
Experiment in vitro shows that TANSHINONES has differentiation of inducing and antitumaous effect, and its anticancer mechanism that presses down cancer is: 1. it is synthetic to suppress cell proliferation and DNA
The flow cytometer testing result shows that TANSHINONES can stop cell in G
0/ G
1Phase makes it can not enter the S phase, thereby suppresses the synthetic and cell proliferation of DNA.TANSHINONES can be expressed by suppressing PCNA (PCNA), influences DNA polymerase δ activity, and it is synthetic to suppress DNA, thereby suppresses cell proliferation, the inducing cell differentiation.2. inducing cell breaks up and apoptosis
Studies show that the curative effect of cancer therapy drug not only depends on the interaction of itself and specific target cell, also depend on the ability of its cell death inducing, tumor cell is the key factor of decision chemotherapy effect to the sensitivity of apoptosis.TANSHINONES can be induced the kinds of tumor cells apoptosis, when inducing differentiation with apoptotic generation, therefore the mechanism of TANSHINONES treatment function of tumor may be the inducing cell differentiation, the while cell death inducing, or inducing tumor cell is divided into mature cell, and these mature cells finally move towards apoptosis.3. to the influence of gene expression
By cell DNA/RNA after the TANSHINONES effect is analyzed discovery, after the TANSHINONES effect, the several genes of tumor cell is expressed and is changed, wherein, the expression of c-myc oncogene obviously reduces, and c-fos gene expression strengthens, it is generally acknowledged, c-myc and c-fos expression of gene are closely related with cell proliferation and differentiation respectively, it is relevant that the amplification of c-myc gene and overexpression and malignant transformation of cells and tumor form, and the decline of its expression then changes with the form of tumor cell and differentiation has substantial connection; The c-fos gene then is the sign of cell differentiation.In addition, after the TANSHINONES effect, also change with closely-related gene p53 of apoptosis and bcl-2 expression, p53 gene and bcl-2 gene are all closely related with apoptosis, the wild type p53 gene can promote the generation of apoptosis, and mutant P 53 gene then has inhibitory action to apoptosis; The bcl-2 gene is then special relevant with apoptosis, the generation of bcl-2 gene apoptosis capable of inhibiting cell, after the TANSHINONES effect, tumor cell bcl-2 gene expression significantly reduces, and p53 gene expression strengthens, and the prompting TANSHINONES is by acting on the tumor differentiation and anticancer, cancer suppressing action is brought into play in the apoptogene expression.4. to the influence of tumor cell telomerase activation
HL60, K562 and APL cell are after 0.5 μ g/ml TANSHINONES acts on 5 days, 9 days, 5 days respectively, and Tan is respectively 30.8%, 50.8% and 37.7% (PCR-TRAP method testing result) to above cell telomerase activation suppression ratio.Telomerase is considered to major part and has the immortality cell of unlimited multiplication capacity and a New Set of tumor cell, suppresses the activity of telomerase, can suppress growth of tumour cell, so downward modulation or inhibition telomerase activation become new approaches of oncotherapy.TANSHINONES has the effect that suppresses HL60, K562 and APL cell telomerase activation, thus prompting, and TANSHINONES may be by suppressing the telomerase activation performance antineoplastic action of tumor cell.
From above result, can be the invention has the advantages that:
1. the present invention has excavated the novel medical use of TANSHINONES, has opened up a new application.
2. TANSHINONES of the present invention derives from the salviamiltiorrhizabung extract, and toxic and side effects is little, and pharmacological action is strong, has good prospect in medicine.
3. raw material of substance of the present invention source is abundant, inexpensive, and preparation technology is simple, has good commercial application prospect.
4. the medicine of material preparation of the present invention has the good result of treatment tumor, by inhibition tumor cell proliferation, inducing tumor cell differentiation and apoptosis, and inhibited to kinds of tumor cells.
5. the medicine of the material preparation of the present invention of non-toxic has differentiation of inducing and apoptosis-induced effect to tumor cell, show by experiment in vivo and vitro, but the TANSHINONES inducing tumor cell of non-toxic is to mature cell or terminal cell differentiation, and the inhibition growth of tumour cell, the new way of having opened up oncotherapy.
6. show through clinical experiment, tablet, capsule, injection and the oral liquid of TANSHINONES preparation of the present invention are evident in efficacy, relatively do not have significant difference with the differentiation agent all-trans-retinoic acid of inducing of present use, and have no side effect and the drug resistance phenomenon, good potential applicability in clinical practice is arranged.
Fig. 1 is the molecular structural formula of 15 kinds of compositions of Radix Salviae Miltiorrhizae.
Below by description, further specify but do not limit the present invention the embodiment of the invention.
The experiment of embodiment 1 animal vivo antitumor
The NIH mice, body weight 20~24 grams, male and female all have, and provide (certificate number: No. the 67th, the real moving pipe in river) by laboratory animal room of Sichuan Province's antibiotics industrial research institute.Each experiment sex is identical, every treated animal number>10.Rat liver cancer H
22Protecting kind by the attached First Academy of Huaxi Medical Univ institute of oncology goes down to posterity.Tanshinone (Tan IIA) provide standard substance by Nat'l Pharmaceutical ﹠ Biological Products Control Institute, lot number 766-9204.Be dissolved to required concentration (experiment final concentration<0.02%) with 10% dimethyl sulfoxine (DMSO) before using.Lotus hepatocarcinoma H gets in the sterile working
22Mouse ascites is diluted to and contains 1 * 10
7/ ml oncocyte, every Corium Mus is inoculated 0.2ml down.At random be divided into 3 group with animal next day: blank group, the isopyknic DMSO of subcutaneous injection; Positive controls, lumbar injection chemotherapeutics fluorouracil (5-Fu), 3mg/kg body weight; Experimental group, subcutaneous injection Tan IIA, 20mg/kg body weight; Repeat 3 times.Each treated animal number and administration number of times see Table 1.Next day is put to death animal in drug withdrawal, dissects and peels off tumor, claims that tumor heavily reaches body weight, calculates tumour inhibiting rate and carries out statistical procedures with the t check, the results are shown in Table 2.Each organizes tumor specimen 20% formalin fixed, specimens paraffin embedding slices, HE dyeing, om observation.
Table 2 tanshinone is to rat liver cancer H
22The heavy tumour inhibiting rate P of the average tumor of inhibitory action experiment number drug dose approach number of times animal number of elements body weight change value
(mg.kg
-1.d
-1) (g) x ± s at the whole story (g) (%)
1 DMSO 10ml SC×5 10 10 +2 1.00±0.31
5-Fu 30mg Ip×4 11 11 -0.5 0.44±0.34 56.0 <0.01
TanIIA 20mg SC×5 10 10 +7 0.50±0.38 50.0 <0.01
2 DMSO 10ml SC×5 14 14 +0.5 1.69±0.50
5-Fu 30mg Ip×4 14 14 +3.5 0.91±0.27 46.2 <0.01
TanIIA 20mg SC×5 12 12 +3.1 1.04±0.47 38.5 <0.01
3 DMSO 10ml SC×5 16 16 +4.2 1.06±0.38
5-Fu 30mg Ip×4 16 16 +2 0.48±0.36 54.7 <0.01
Annotate TanIIA 20mg SC * 5 12 12+4.5 0.63 ± 0.33 40.6<0.01: SC is that subcutaneous injection: ip is a lumbar injection
There were significant differences in P<0.01
The result shows that tanshinone is to rat liver cancer H
22Obvious suppression effect (P<0.01) is arranged, and the weight of animals variation and ordinary circumstance are not had obvious influence.Find that through pathological study each treated animal tumor tissues all has cancerous cell karyopycnosis, lamellar necrosis, hemorrhage and cell infiltration in various degree, experimental group obviously overweights matched group.Induce the experiment of differentiation and anti metastasis in embodiment 2 animal bodies
The BALB/C mice height of In vitro culture is shifted pulmonary carcinoma (Lewis) cell with 5 * 10
6/ ml cell number is inoculated in the subcutaneous 0.2ml in BALB/C mice back, and at random be divided into 3 group with animal next day, 10 every group: blank group, the isopyknic DMSO of subcutaneous injection; Positive controls, lumbar injection chemotherapeutics fluorouracil (5-Fu, 3mg/kg body weight); Experimental group is TanIIA (the 20mg/kg body weight is irritated stomach) and tanshinone capsule (preparation method is stated as follows, and 20mg/kg irritates stomach), once a day, totally 10 days, continued letting animals feed again 13 days, dead until there being animal to occur.Put to death animal, dissect and peel off tumor, claim that the weight of animals, tumor weigh, lung heavily reaches and observes the lung tumors metastasis, calculate tumour inhibiting rate and neoplasm metastasis suppression ratio, and carry out statistical procedures with the t check, each organizes tumor specimen 20% formalin fixed, specimens paraffin embedding slices, HE dyeing, om observation.
PRELIMINARY RESULTS shows that TANSHINONES can suppress lung carcinoma cell and form ability in the intravital tumor of mice, and can suppress the lung transfer of primary tumo(u)r.
Human clinical's experiment
Embodiment 3 medication preparation
The preparation process of tanshinone capsule:
Material: Radix Salviae Miltiorrhizae (Salvia mltiorrhiza Bge.) is available from Chengdu Chinese crude drug company, medicinal alcohol (inland river Alcohol Plant), standard reference material tanshinone (Nat'l Pharmaceutical ﹠ Biological Products Control Institute).
Method: measure 65% soak with ethanol Radix Salviae Miltiorrhizaes after 24 hours with 12 times, with flow per hour is 1/2 speed percolation of medical material weight, with the tanshinone is that standard reference material is measured the total tanshinone content in the solution that obtains, become solids with reference to the official method concentrate drying, after weighing, calculate the extract response rate, add pharmaceutically acceptable carrier or excipient and optional additional components, make and be suitable for orally such as capsule, cachet or tablet, each capsule, cachet or tablet contain the TANSHINONES of scheduled volume.
The applying high voltage chromatograph of liquid tests that tanshinone content is 2.5mg in the every capsules of clinical usefulness.
Clinical trial
Below for before the human clinical that Subsidiary Hospital No.1, Huaxi Medical Univ carries out, reaching the methodology and the result of clinical trial.The purpose of described test is to determine the effect of TANSHINONES treatment tumor and to the effectiveness and the toxic and side effects of human body.
Embodiment 4 TANSHINONES are to the treatment curative effect of acute promyelocytic leukemia (APL)
Therapeutic outcome with the early young grain leukemia patient of an example is an example:
Method 1) 1. to include standard: A. in be promyelocytic leukemia (M by the FAB standard diagnostics to patient's choice criteria
3) patient;
B. without other chemotherapeutics therapist;
C. do not alleviate or the recidivist through retinoic acid treatment.2. exclusion standard: the state of an illness is critical can not finish 3-4 week therapist.2) treat the course of treatment
Non-blind method randomized controlled trial:
Test group: TANSHINONES (capsule) 30mg.tid two months
Matched group: effectiveness retinoic acid (capsule) 20mg.tid two months 3)
Treat effectiveness according to the criterion of therapeutical effect evaluation that national leukemia meeting in 1987 is formulated.Clinical data:
Chen Youyuan, man, 30 years old.Excuse is confused, weak, the mucocutaneous hemorrhage first quarter moon, goes to a doctor in the outpatient service of hematology of the attached First Academy of Huaxi Medical Univ.The demonstration of having a medical check-up: whole skin is dispersed in petechia and purpura, anemia looks, and liver, splenic lymph nodes do not have enlargement.Be diagnosed as acute promyelocytic leukemia through hemogram and bone marrow examination.Use retinoic acid 20mg, three times on the one oral 77 days, do not have and alleviate hemoglobin (Hb); 96g/L, leukocyte (WBC): 2.3 * 10
9/ L, platelet (BPC): 209 * 10
9/ L, classification (DC): variation lymph 0.11, neutrophilic granulocyte 0.25, lymph 0.74, the bone marrow nucleated cell active proliferation, promyelocyte accounts for 0.77.Use TANSHINONES 30mg instead, three times on the one oral medications 27 days, Hb:114g/L, BPC:178 * 10
9/ L, WBC:4.1 * 10
9/ L, TANSHINONES was treated after 54 days, Hb:142 * 10
9/ L, BPC:234 * 10
9/ L, WBC:9.2 * 10
9/ L, DC: no abnormal.Bone marrow smear shows myeloblast 0.005, promyelocyte 0.025, and have a medical check-up no lymph node, liver, splenomegaly reach fully and alleviate, and do not see any toxic and side effects.
Embodiment 5 TANSHINONES are to the in vitro study of acute promyelocytic leukemia (APL) patient's APL cell induction differentiation
Gather 5 examples respectively and just send out the about 5ml of APL patient's bone marrow, separate single granulocyte through Ficoll, with 5 * 10
5/ ml cell concentration is inoculated in six orifice plates, uses 0.5 μ g/ml tanshinone (TanIIA) and 0.5 μ g/ml all-trans-retinoic acid (ATRA) respectively and handles cell, and continuous culture is observation of cell growth and differentiation situation after 7 days, the results are shown in Table 3.
Table 3 Tan IIA and ATRA support the comparison of APL cell differentiation influence to former being commissioned to train
-: C is untreated: negative control T:0.5 μ g/ml tanshinone R:0.5 μ g/ml all-trans-retinoic acid
The sick example day said conditions of cultivating | Bone marrow differentiation rate (%) | Induce NBT differentiation (%) rate (%) |
Children's grain children in evening band form nucleus neutrophil(e) cell cell cell pellets cell pellets cell in the early young grain of former grain | ||
1 0 - 7 C 7 T 7 R 2 0 - 7 C 7 T 7 R 3 0 - 7 C 7 T 7 R 4 0 - 7 C 7 T 7 R 5 0 - 7 C 7 T 78 R | 8.0 91.0 1.0 7.0 85.0 8.0 7.0 15.5 8.5 39.0 30.0 4.0 27.0 2.0 42.0 25.0 10.0 86.0 4.0 6.0 82.0 12.0 4.0 12.0 16.0 49.0 19.0 2.0 13.0 15.0 37.0 33.0 5.0 83.0 12.0 6.0 76.0 18.0 7.5 8.0 17.5 20.0 37.0 19.0 4.0 15.0 14.0 48.0 4.0 72.0 24.0 2.0 66.0 32.0 2.0 6.0 12.0 15.0 32.0 33.0 1.0 8.0 18.0 12.5 33.0 27.5 84.0 16.0 1.0 75.0 22.0 2.0 12.0 19.0 13.0 45.0 11.0 14.0 12.0 21.0 23.0 30.0 | 4.0 85.9 94.0 88.9 98.0 6.0 87.5 90.0 89.6 96.0 7.0 84.1 92.0 88.6 90.0 12.0 78.9 90.0 77.6 90.0 10.0 76.1 86.0 73.8 84.0 |
The result shows: growth has obvious inhibitory action to Tan IIA to patient APL cell, and its growth inhibition ratio is 39.7% (comparing zero difference with ATRA 40.8%); Tan IIA also can obviously promote APL cell differentiation maturation, induces differentiation rate average out to 82.5%.
By above experiment in vivo and vitro result as can be seen, TANSHINONES reaches the purpose for the treatment of tumor by killing tumor cell, inducing tumor cell differentiation and/or apoptosis, and it is evident in efficacy, toxic and side effects is little, has a good application prospect
The invention is not restricted to above embodiment, it will be appreciated by those skilled in the art that and under the prerequisite that does not break away from spirit of the present invention, can make various changes and distortion,, all fall within the scope of the invention as long as relate to the new purposes of TANSHINONES treatment tumor.
The main reference document: 1. Qian Mingkun, Yang Baojin, Gu Wenhua, etc. the research of effective component in red sage. chemical journal 1978; 36:199-2052. Li Shizhen (1518-1593 A.D.). Compendium of Materia Medica (this second of check and punctuate). Beijing: People's Health Publisher .1977; 7593. its year of room, Zhang Peiling, Xu Zongpei. the research of Radix Salviae Miltiorrhizae antibiotic effective ingredient. chemical journal 1976; 34 (3): 197-2094. Cao's grace China, Liu Xiaoqi, Li Jingfu, etc. Natural antioxidant tanshinone is to hepatoma carcinoma cell lipid peroxidation product and the interactional influence of DNA. Acta Biophysica Sinica 1996; 12 (2): 339-3445. opens civilian army, Bao Xiaofeng, and Wang Xiufeng, etc. sodium tanshinone IIA sulfate suppresses macrophage source property factors stimulated growth smooth muscle cell c-myc gene expression. Chinese arteriosclerosis magazine 1996; 4 (4): the 45-476. Huang is prosperous, hides beneficial bright. sodium tanshinone IIA sulfate cardiovascular pharmacological, foreign medical science Chinese medicine fascicle 1995; 17 (1): the long slowly celebrating of 9-127., Wang Xiaoming, the model sturdy pines, etc., tanshinone is to the influence of single ventricular muscle cell transmembrane potential of Cavia porcellus and L-type calcium current. Chinese pathophysiology magazine 1997; 13 (10; 443-478. Gao Yugui, Song Yumei, the poplar friend, etc. PHARMACOLOGY OF TANSHINONE. Acta Pharmaceutica Sinica 1979; 14 (2): 75-819. Chen Hui core. leukemia is induced the progress of differentiation therapy experimental methodology. leukemia 1996; 5 (1): 56-5910.Huang ME, Chen YY, Weng ZY, et al.Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.Blood 1988; 72 (2); 567-57211. Wang Zhen justice, Sun Guanlin, Chen Zhu. induce differentiation therapy to use present situation. Chinese Journal of Hematology 1994; 15 (20): 105-10712.Wang ZY, Chen Z, Huang Wet al.Problems existing in differentiation therapy of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) .Blood Cell 1993; 19:633-64113. Wang Zhen justice, Chen Zhu. tumor induce differentiation and leukemia and apoptosis therapy. Shanghai science tech publishing house 1998
Claims (2)
1. TANSHINONES or the application of pharmaceutical composition in preparation medicine for treating tumor thing that contain TANSHINONES, wherein said tumor is a human leukemia.
2. application according to claim 1, wherein said TANSHINONES are tanshinone or its pharmaceutically acceptable salt.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 99121460 CN1126539C (en) | 1999-10-26 | 1999-10-26 | Application of tanshinone in preparing medicine for treating tumor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 99121460 CN1126539C (en) | 1999-10-26 | 1999-10-26 | Application of tanshinone in preparing medicine for treating tumor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1264580A CN1264580A (en) | 2000-08-30 |
CN1126539C true CN1126539C (en) | 2003-11-05 |
Family
ID=5281993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 99121460 Expired - Fee Related CN1126539C (en) | 1999-10-26 | 1999-10-26 | Application of tanshinone in preparing medicine for treating tumor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1126539C (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002362159A1 (en) * | 2002-12-31 | 2004-07-22 | Zhongshan Univertsity | Tanshinone iia for prophylaxising or treating atherosclerosis |
TW201240658A (en) * | 2011-04-07 | 2012-10-16 | Univ Central Taiwan Sci & Tech | Pharmaceutial composition capable of indncing death of tumor cells |
CN102579461A (en) * | 2012-01-12 | 2012-07-18 | 中国药科大学 | Application of tanshinone IIA in preparation of medicament for treating p53 mutational or deficient tumor |
CN103479649B (en) * | 2013-08-09 | 2016-01-27 | 大连理工大学 | A kind of pharmaceutical composition and application thereof |
TWI723030B (en) | 2015-07-01 | 2021-04-01 | 長庚醫療財團法人嘉義長庚紀念醫院 | Dihydroisotanshinone i use for treating cancer |
CN110201017A (en) * | 2019-06-28 | 2019-09-06 | 曹文 | Arasaponin combines application of the tanshinone IIA in preparation prevention colorectal cancer drug |
CN113940936A (en) * | 2021-10-01 | 2022-01-18 | 浙江中医药大学 | Application of dihydrotanshinone I in preparation of Nrf2 inhibitor |
-
1999
- 1999-10-26 CN CN 99121460 patent/CN1126539C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1264580A (en) | 2000-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1126539C (en) | Application of tanshinone in preparing medicine for treating tumor | |
Wang et al. | Metformin suppresses LPS-induced inflammatory responses in macrophage and ameliorates allergic contact dermatitis in mice via autophagy | |
CN113925867A (en) | Application of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs | |
CN101032478A (en) | Application of triptolide in the preparing of anti-alimentary tract tumor medicine | |
CN1823787A (en) | Application of lucid ganoderma acid in preparation of cancer transfer inhibitor | |
Larasati et al. | Naringenin enhances the anti-tumor effect of doxorubicin on HeLa cervical cancer cells through cytotoxic activity and apoptosis induction | |
CN105399794A (en) | Fructus momordicae triterpene saponin and salt thereof, preparation method and applications of fructus momordicae triterpene saponin and salt thereof, and pharmaceutical composition containing fructus momordicae triterpene saponin and salt thereof | |
CN112402413B (en) | Application of lindley eupatorium herb sesquiterpene lactone B in preparation of anti-liver cancer medicine and anti-liver cancer medicine | |
CN104069194A (en) | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof | |
CN101862313A (en) | Application of anthracycline compound in preparing anti-breast cancer medicines | |
CN106334108B (en) | Medicinal composition of functional red yeast active ingredient and docosahexaenoic acid and application thereof in preparing antitumor medicament | |
CN101590103B (en) | Traditional Chinese medicine combination for treating leukemia and preparation method thereof | |
CN100515461C (en) | Gamboge soft paste preparation | |
US20230201294A1 (en) | Aqueous extraction process of plants, method thereof, and product by process | |
CN101590092A (en) | A kind of leukemic Chinese medicine composition and preparation method thereof that is used for the treatment of | |
CN1939311A (en) | Ginseng sapogenin aglycone derivative biological preparation and its usage | |
CN113133994B (en) | Application of tricyclic diterpene natural product Vinigrol or pharmaceutical composition thereof in preparation of anti-cancer drugs | |
CN101292974B (en) | Pharmaceutical use of diacetyl diphenyl sulphone heptane in preventing and controlling chronic marrow-derived leukocythemia | |
CN113368090B (en) | Application of 3, 4-seco cycloartenane type tetracyclic triterpene compound or pharmaceutically acceptable salt thereof in preparation of anticancer drugs | |
CN101336918B (en) | Use of annonaceous acetogenins in preparing medicine for treating lung cancer or breast cancer | |
CN108014119B (en) | Application of phenylpropanoid glycoside Smiglaside A in preparation of medicine for treating sepsis | |
Ukwubile et al. | Application of Melastomastrum capitatum Fern.(Melastomataceae) loaded-exosome as analgesic drug carrier in acetic acid-induced Swiss albino mice | |
CN101401820B (en) | Injection novel medicine for treating systematic lupus erythematosus | |
Fan et al. | Study on mechanism of Radix astragali-Lithospermum erythrorhizon in treatment of diabetic ulcer based on network pharmacology. | |
TWI635867B (en) | Use of herbal composition in preparation drug for inhibiting tumor cell metastasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: HUAXI HOSPITAL ATTACHED TO SICHUAN UNIV. Free format text: FORMER NAME OR ADDRESS: SUBSIDIARY HOSPITAL NO.1, HUAXI MEDICAL UNIV. |
|
CP01 | Change in the name or title of a patent holder |
Patentee after: WEST CHINA HOSPITAL OF SICHUAN University Patentee before: NO 1 HOSPITAL ATTACHED TO HUAX |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1057496 Country of ref document: HK |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |